Hydroxychloroquine in prevention of sever forms of COVID-19 in healthcare workers

Phase 2

• Conditions: COVID-19.; COVID19, virus identified; U07.1

• Registration Number: IRCT20200424047184N1
• Lead Sponsor: Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Healthcare workers and students of Islamic Azad University Tehran Medical Branch(IAUTMU) affiliated hospitals.
Age 18-70 years
No symptoms of COVID19 at the time of registration
No history of COVID-19 diagnosis within the past 3 months from joining the study
Desire to participate in the study and filling out the consent form

Exclusion Criteria

Any of COVID-19 symptoms at registration: fever, chills, cough, dyspnea,runny nose, loss of smell, loss of taste, headache, sore throat, chest pain, abdominal pain, nausea, vomiting, diarrhea, malaise and musculoskeletal pain
History of COVID-19 within the past 3 months
Contraindications for hydroxychloroquine including allergy to hydroxychloroquine , G6PD, Long QT Syndrome, porphyria, retinopathy
Pregnancy
Sever kidney or liver disease
HIV, AIDS
Systemic lupus erythematosus, rheumatoid arthritis
active cancer

Study & Design

• Study Type: interventional
• Study Design: Not specified